Navigation Links
Phase Genomics Announces the Commercial Availability of ProxiMeta™ Hi-C
Date:5/16/2017

Seattle-based Phase Genomics announced today the general availability of its new ProxiMeta™ Hi-C metagenomic deconvolution service. ProxiMeta enables researchers to obtain complete, distinct genomes from microbiome samples easily and affordably—without culturing or high-molecular-weight DNA extraction—speeding research insights at lower cost.

“We’re very excited about the commercial launch of our newest service for metagenomic assembly,” said Dr. Ivan Liachko, CEO and Co-founder of Phase Genomics. “ProxiMeta will help researchers answer longstanding, fundamental questions about their microbial samples. We give customers a way to explore the dark matter of the microbiome by quickly assembling the many genomes contained in a sample, leading to answers they could not have found otherwise.”

Microbial communities are typically made up of many different species living together. Standard methods for sequencing these communities mix together information from all the microbes in the sample. The result is a hodgepodge of genes that is challenging to analyze, and unknown species in the sample are difficult to discover. The innovative ProxiMeta Hi-C method reveals which DNA sequences originated in the same cell, enabling the assembly of whole genomes from mixed microbial samples in their natural state.

"Phase Genomics' ProxiMeta Hi-C solution makes innovative use of Illumina reads to conduct metagenomic deconvolution and extract more complete sequence information from mixed microbiome samples,” said Gary Schroth, PhD, Vice President of Genomics Development and Distinguished Scientist for Illumina. “This technology promises to open many new metagenomic applications and we’re excited to see it come to market."

CLEAR RESEARCH BENEFITS

By combining Hi-C proximity data and metagenomic sequencing, ProxiMeta delivers benefits not available from other methods.

  • Clarity. Gain a more detailed view of microbial communities using the only method that moves straight from a raw sample to scores, or hundreds, of individual, reference-quality genomes.
  • Simplicity. Simply collect and send in a microbial sample. No culturing is required, saving time and cost.
  • Velocity. With publication-ready data typically available in 30 days, researchers can find and publish new insights faster.

"ProxiMeta Hi-C facilitates the cultivation-independent assembly of bacterial genomes present in complex microbial communities. Of particular interest is its potential to associate plasmids with their host genomes. Without having to culture individual isolates, ProxiMeta offers a new approach to examine the reservoirs of mobile genetic elements that carry genes of interest, such as toxin or antimicrobial resistance genes,” said Professor Eva Top, Bioinformatics and Computational Biology Graduate Program Director at the University of Idaho.

A SIMPLE PROCESS

ProxiMeta Hi-C is based on capturing physical DNA proximity with in vivo Hi-C. This allows sequences from the same species and/or strain to be grouped, yielding a large number of genomes for rare, unculturable, and novel microbes. The ProxiMeta Hi-C service is a straightforward process for researchers:

  • Researchers contact Phase Genomics to obtain a quote
  • Researchers collect a raw sample (for example, a fecal or soil sample) and send it to Phase Genomics
  • Phase Genomics processes the sample, providing shotgun sequencing, assembly, and metagenomic deconvolution
  • Phase Genomics delivers the resulting genomes, along with supplementary figures and reports, to a secure online location for customer access, typically within 30 days of receiving a sample

Interested parties can learn more about ProxiMeta and other Phase Genomics services by visiting the Phase Genomics table at the Sequencing, Finishing and Analysis in the Future (SFAF) conference May 16-18, or at http://www.phasegenomics.com.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14333703.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
2. Former FDA Official to Conduct Popular ComplianceOnline Seminar on FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
3. Phase Genomics and Phyzen Co., Ltd. Announce Korean Distribution Partnership
4. Histogen and Worcester Polytechnic Institute Receive Phase II NSF Award to Develop Unique Wound Treatment
5. 2-Day Seminar FDAs GMP Expectations for Phase I and First-in-Man Clinical Trials by Ex-FDA Official (Tampa, FL, United States - May 18-19, 2017) - Research and Markets
6. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
7. Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis
8. RepliCels Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints
9. Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
10. SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients
11. OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Intralytix, Inc. announced that it received $17.5 million in ... This investment marks the beginning of a close collaboration ... for various benefits in human health and in other ... As a global key player in yeasts ... for baking, food taste & pleasure, health care, and ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... leading radiology and imaging centers around the U.S. that offer MR Elastography for ... alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect was ...
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health ... announced its full advisory board. The board comprises leaders spanning business, technology, academia, ... PhD, former VP of Engineering, to Chief Technology Officer. Crooks will lead strategy ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):